- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 19/00 - Peptides hybrides
Détention brevets de la classe C07K 19/00
Brevets de cette classe: 10052
Historique des publications depuis 10 ans
470
|
577
|
572
|
759
|
787
|
842
|
926
|
858
|
761
|
216
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
The Regents of the University of California | 18943 |
178 |
The Trustees of the University of Pennsylvania | 4122 |
98 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
68 |
Acceleron Pharma Inc. | 365 |
68 |
National Research Council of Canada | 1545 |
63 |
Regeneron Pharmaceuticals, Inc. | 3650 |
55 |
F. Hoffmann-La Roche AG | 7958 |
53 |
Osaka University | 3143 |
52 |
The General Hospital Corporation | 4517 |
51 |
JCR Pharmaceuticals Co., Ltd. | 206 |
46 |
The University of Tokyo | 3903 |
46 |
Chugai Seiyaku Kabushiki Kaisha | 1259 |
45 |
Amgen Inc. | 3779 |
43 |
Immatics Biotechnologies GmbH | 1144 |
42 |
Board of Regents, The University of Texas System | 5370 |
41 |
President and Fellows of Harvard College | 5792 |
40 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
39 |
The Johns Hopkins University | 5377 |
38 |
Dana-Farber Cancer Institute, Inc. | 2455 |
37 |
Sangamo Therapeutics, Inc. | 437 |
35 |
Autres propriétaires | 8914 |